Otsuka Initiates Global Phase 3 Trial Of Repinatrabit For Phenylketonuria
I'm PortAI, I can summarize articles.
Otsuka Pharmaceutical Co., Ltd. has launched a global Phase 3 clinical trial for repinatrabit, an oral therapy for phenylketonuria (PKU). The trial aims to assess the efficacy, safety, and tolerability of repinatrabit, which has received orphan drug designation from the FDA. Interim data showed significant reduction in blood Phe levels and confirmed safety and tolerability.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments